The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.
A 21-year-old started using topical minoxidil, finasteride (0.7 mg), and microneedling for hair loss treatment after beginning to bald at 18. They are eager to see the results after two months of treatment.
Anxious_Bee_67's 4 month progress with a hair loss treatment regimen of 1 mg oral finasteride once a day and topical minoxidil twice a day, which has brought "hope" to others who are fighting the Norwood Reaper. Replies include encouragement for further progress and advice on other treatments that can be used in conjunction with the current ones.
The user is using oral finasteride, topical minoxidil, and microneedling for hair loss. Progress has slowed, with the crown showing little change, but the hairline is improving with more thin baby hairs.
PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses the use of peptides C60 and GHK-Cu for hair growth. Participants are sharing their experiences or knowledge about these treatments.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Various hair growth treatments were discussed, including microneedling, bimatoprost, setipiprant, stemoxydine, PGE2, CB-03-01, WNT Beta-Catenin upregulators, KY19382, topical estrogen, IGF-1, GH, MK-677, oral castor oil, fisetin, resveratrol, cetrizine, and lactic acid. Users shared experiences and sources for these treatments, with some expressing interest in topical solutions and others noting the lack of FDA approval or scientific evidence for certain options.